The new firm, Grüneberg and Myers, will provide strategic patent counseling to clients ranging from startups to multinational corporates.
Joining them is another former Oblon attorney, Richard Chinn, who focuses on chemical patents.
Overall, the firm will cover the chemical, materials science, life science and pharmaceutical fields.
Grüneberg focuses on chemical, biotech and pharmaceutical companies, while Myers works on patentability, invalidity and non-infringement issues.
Grüneberg said the firm plans to take a “diversity-minded approach to attract the best talent in patent law”.
She added: “Our differences and diverse perspectives make us stronger.”
Myers added that the firm would weather industry changes, such as the introduction of the America Invents Act and various uncertain Supreme Court decisions, “by providing high-quality service through a low-overhead framework”.
He said: “We have strategically designed our firm with a keen eye on every dollar to ensure that we remain agile and lean. Minimised overhead will free us up to treat every case with individualised care. We won’t need to churn through volume quickly just to stay profitable.”